



STATE MEDICAID P&T COMMITTEE MEETING
THURSDAY, November 19, 2009
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114



MINUTES

Committee Members Present:

Ellie Brownstein, M.D.
Brandon Jennings, PharmD.
Raymond Ward, M.D.

Michael Flynn, M.D.
Duane Parke, R.Ph.
Kort DeLost, R.Ph.

Board Members Excused:

Karen Gunning, PharmD.

Jerome Wohleb, PharmD.

Dept. of Health/Div. of Health Care Financing Staff Present:

Jennifer Zeleny, CPhT., MPH
Tim Morley, R.Ph.

Lisa Hulbert, R.Ph.

University of Utah Drug Information Center Staff Present:

Chris Beckwith, PharmD.

Other Individuals Present:

Roy Lindfield, Schering/Merck
Mary Shefchyk, NNI
Vilayvone Thipsovan, Pharmacy Student

Ken Brier, Schering/Merck
Julie Smith, Pharmacy Student

Meeting conducted by: Raymond Ward, M.D., Co-Chairperson.

-
1. Minutes for October 2009 were reviewed, corrected, and approved. Duane moved to approve the minutes. Dr. Brownstein seconded the motion. The motion was approved with unanimous votes by Dr. Brownstein, Dr. Jennings, Duane Parke, Kort DeLost, and Dr. Ward.
 2. Housekeeping: Duane Parke addressed the Committee. From time to time, new drugs are approved for existing classes, Kapidex being one case. Some of them come with attractive bids. He does not want to take an entire hour re-reviewing the class, so Dr. Beckwith proposed that she could put together a comparison of the new agents compared to the rest of the class and email it to the Committee for approval.

The Committee asked how often these cases come up. There are two or three that have come out in this last year.

Dr. Ward asked if this could be handled only by email, or if it would need to be voted on in a meeting. Duane said he would need to ask the attorneys. Dr.

Beckwith proposed that perhaps she could do one new agent in a meeting along with an entire class. Dr. Ward said that would be fine, if Dr. Beckwith judged that there was not a lot of data and would not be a very controversial topic.

Duane stated that Hepatitis C was approved by administration. Both Peg interferons 2A and 2B would be preferred. On the targeted immunomodulators, both Enbrel and Humira would be preferred. He has not yet gotten a response on the third generation cephalosporins or second generation anti-histamines.

3. Election of a New Co-Chair: Dr. Ward addressed the Committee. A new Co-Chair needs to be elected. Traditionally, there has been one physician and one pharmacist Co-Chair, but this is not written into rule.

Election was deferred until Karen Gunning returns from maternity leave.

4. DUR Board Update: Lisa Hulbert addressed the Committee. The last DUR Board meeting on November 12 did not occur due to a lack of quorum. In October, the DUR Board placed a PA and quantity limit on Nucynta. The PA requirement on Cancidas was removed due to low volume and almost 100% approval rate. Quantity limits were also placed on insulin to prevent diversion and fraud.
5. Fluoroquinolones (oral): Dr. Christina Beckwith of the University of Utah Drug Information service presented a report prepared by the University.

Ken Brier, Medical Science Liaison from Schering Plough spoke in favor of Avelox and its gram positive activity in respiratory infections.

Duane noted that all of the fluoroquinolones have the black box warning for tendonopathy.

Dr. Ward stated that based on Dr. Beckwith's presentation they all seem similar, except that there is second generation in one category, and third and fourth generation in the other category. The lion's share of utilization is split between ciprofloxacin and levofloxacin, with a small amount of utilization in moxifloxacin. Gemifloxacin has three prescriptions per year.

Dr. Beckwith stated that the P&T Committee probably does not want to have norfloxacin as the only preferred. Dr. Brownstein stated that there are rare instances where oral liquids are needed for children and adults who cannot swallow tablets.

The Committee expressed concerns over the delay in care related to the change in availability in antibiotics. Dr. Ward stated that their recommendation could include a statement that the PDL include something that the current highly utilized branded drug (Levaquin) be included.

Jennifer Zeleny explained that a pharmacist can, in their professional

judgment, dispense a 72 hour supply in an emergency situation. This has been published in the last several Amber Sheets to raise provider awareness. The pharmacists on the Committee agreed that most pharmacists would dispense a short supply of an antibiotic and figure out payment later.

Kort asked Dr. Beckwith to repeat what has coverage for gram positive versus gram negative, and what has coverage for community acquired pneumonia. Most trials did not look at gram positive versus gram negative, but looked at bacterial eradication. She reviewed the results of the report.

Dr. Ward suggested breaking out two separate motions – one to cover second generation agents and one to cover third and fourth generation agents.

Dr. Biel commented that industry must design studies utilizing accepted appropriate therapies as comparators, due to ethical constraints. This is why not all of the drugs have head-to-head studies. Secondly, there is a difference in rates of resistance in the community between the agents for gram-positive infections.

Dr. Flynn moved that ciprofloxacin be included as its own category due to its range of indications, and include at least one oral liquid form. Dr. Brownstein seconded the motion. The motion was approved with unanimous votes by Dr. Brownstein, Dr. Jennings, Duane Parke, Kort DeLost, Dr. Flynn, and Dr. Ward.

The Committee felt that there were enough differences in coverage of gram-positive anaerobes that coverage of both should be provided. The physicians also wanted to ensure that levofloxacin, the only third generation agent under consideration, be included in the PDL.

Dr. Flynn moved that at least one third generation and at least one fourth generation agent should be included. Kort seconded the motion. The motion was approved with unanimous votes by Dr. Brownstein, Dr. Jennings, Duane Parke, Kort DeLost, Dr. Flynn, and Dr. Ward.

Next Meeting Set for Thursday, December 17, 2009
Meeting Adjourned.

Minutes prepared by Jennifer Zeleny